SPATS2

Across TCGA pan-cancer cohorts, SPATS2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SPATS2 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SPATS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPATS2 expression acts as an unfavorable survival marker, although some lineages such as COAD and UCEC show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where SPATS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.204	0.774	<.001	71	view →
COAD	DFS	Median	All	1.000	0.914	.015	30	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	17	view →
UCEC	DFS	Tertile	II,III,IV	0.808	0.405	.036	4	view →
GBM	DFS	Tertile	All	0.408	0.204	.037	2	view →
LSCC	DFS	Median	III,IV	0.470	0.817	.033	2	view →
HNSC	DFS	Quartile	II,III,IV	0.858	0.973	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SPATS2–CCRCC (DFS)

Open the CCRCC breakdown →